Use of adjuvants for immunotherapy

被引：28

作者：

Circelli, Luisa ^{[1
]}

Tornesello, Marialina ^{[1
]}

Buonaguro, Franco M. ^{[1
]}

Buonaguro, Luigi ^{[1
]}

机构：

[1] Fdn Pascale IRCCS, Ist Nazl Studio & Cura Tumori, Lab Mol Biol & Viral Oncol, Naples, Italy

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2017年 / 13卷 / 08期

基金：

欧盟第七框架计划;

关键词：

adjuvant; cancer immunotherapy; cancer vaccine; Toll-like receptors; PATTERN-RECOGNITION RECEPTORS; RNA-BASED ADJUVANT; PHASE-II TRIAL; INNATE IMMUNITY; VACCINE; CANCER; RESPONSES; SAFETY; TOLL-LIKE-RECEPTOR-2; ENGAGEMENT;

D O I：

10.1080/21645515.2017.1321725

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.

引用

页码：1774 / 1777

页数：4

共 46 条

[1]

Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P626

[2]

Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity [J].

Asprodites, Nicole ;

Zheng, Liqin ;

Geng, Degui ;

Velasco-Gonzalez, Cruz ;

Sanchez-Perez, Luis ;

Davila, Eduardo .

FASEB JOURNAL, 2008, 22 (10) :3628-3637

[3]

Universal hepatitis B immunization: infant, and infant plus adolescent immunization [J].

Bonanni, P .

VACCINE, 1998, 16 :S17-S22

[4]

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant [J].

Borsutzky, S ;

Ebensen, T ;

Link, C ;

Becker, PD ;

Fiorelli, V ;

Cafaro, A ;

Ensoli, B ;

Guzmán, CA .

VACCINE, 2006, 24 (12) :2049-2056

[5]

New adjuvants in evolving vaccine strategies [J].

Buonaguro, Franco M. ;

Tornesello, Maria Lina ;

Buonaguro, Luigi .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) :827-832

[6]

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis [J].

Chakravarty, Jaya ;

Kumar, Subodh ;

Trivedi, Sonali ;

Rai, Vijay K. ;

Singh, Anup ;

Ashman, Jill A. ;

Laughlin, Elsa M. ;

Coler, Rhea N. ;

Kahn, Stuart J. ;

Beckmann, Anna Marie ;

Cowgill, Karen D. ;

Reed, Steven G. ;

Sundar, Shyam ;

Piazza, Franco M. .

VACCINE, 2011, 29 (19) :3531-3537

[7]

PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine [J].

Cheever, Martin A. ;

Higano, Celestia S. .

CLINICAL CANCER RESEARCH, 2011, 17 (11) :3520-3526

[8]

Immunological effects of a novel RNA-based adjuvant in liver cancer patients [J].

Circelli, Luisa ;

Petrizzo, Annacarmen ;

Tagliamonte, Maria ;

Heidenreich, Regina ;

Tornesello, Maria Lina ;

Buonaguro, Franco M. ;

Buonaguro, Luigi .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (01) :103-112

[9]

Cluff CW, 2009, ADV EXP MED BIOL, V667, P111, DOI 10.1007/978-1-4419-1603-7_10

[10]

Cancer Immunotherapy [J].

Couzin-Frankel, Jennifer .

SCIENCE, 2013, 342 (6165) :1432-1433

← 1 2 3 4 5 →